Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-22T08:55:15.377Z Has data issue: false hasContentIssue false
  • English
  • Français

Depot Antipsychotics in the Prophylaxis of Bipolar Affective Disorder

Published online by Cambridge University Press:  02 January 2018

R. Littlejohn ,
F. Leslie  and
J. Cookson
R. Littlejohn
Affiliation:
Academic Unit of Human Psychopharmacology, Royal London Hospital, London
F. Leslie
Affiliation:
Academic Unit of Human Psychopharmacology, Royal London Hospital, London
J. Cookson*
Affiliation:
Academic Unit of Human Psychopharmacology, Royal London Hospital, London
*
Dr J. Cookson, Academic Unit of Human Psychopharmacology, Royal London Hospital, St. Clement's, 2A Bow Road, London E3 4LL
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

The efficacy of depot antipsychotic drugs in the prophylaxis of bipolar affective disorder was investigated.

Method

Life charts were constructed for 18 outpatients with bipolar disorder receiving prophylactic treatment with depot medication. The durations of affective episodes were compared during periods on or off medication.

Results

The subjects suffered fewer relapses and spent significantly less time in hospital (P = 0.001) for treatment of manic, depressive and mixed affective illness during treatment with depot antipsychotics.

Conclusions

Depot antipsychotic medication may be a useful prophylactic treatment for certain patients with bipolar affective disorder.

British Journal of Psychiatry (1994), 165, 827–829

Type
Research Article
Information
The British Journal of Psychiatry , Volume 165 , Issue 6 , December 1994 , pp. 827 - 829
Copyright
Copyright © Royal College of Psychiatrists, 1994 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ahlfors, U. G., Baastrup, P. C., Dencker, S. J., et al (1981) Flupenthixol decanoate in recurrent manic depressive illness. Acta Psychiatrica Scandinavica, 64, 226–237.Google Scholar
Coppen, A., Noguera, R., Bailey, J., et al (1971) Prophylactic lithium in affective disorders: controlled trial. Lancet, 2, 275–279.Google Scholar
Esparon, J., Kalloor, J., Naylor, G. J., et al (1986) Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic depressive patients. British Journal of Psychiatry, 148, 723–725.Google Scholar
Lowe, M. & Batchelor, D. (1986) Depot neuroleptics and manic depressive psychosis. International Journal of Clinical Psychopharmacology, 1 (suppl. 1), 53–62.Google Scholar
Maarbjerg, K., Aagaard, N., Vestergaard, P., et al (1988) Adherence to lithium prophylaxis I. Clinical predictors and patient's reasons for non-adherence. Pharmacopsychiatry, 21, 121–125.Google Scholar
Naylor, G. & Scott, C. (1980) Depot injections for affective disorders. British Journal of Psychiatry, 136, 105.Google Scholar
Prien, R. F., Caffey, E. M. Jr, Klett, C. J., et al (1973) Prophylactic efficacy of lithium carbonate in manic depressive illness. Archives of General Psychiatry, 28, 337–341.Google Scholar
Squillace, B. S. & Post, R. (1984) Life charting of the longitudinal course of recurrent affective illness. In Neurobiology of Mood Disorders (eds Post, R. & Ballenger, J.). Baltimore: Williams & Wilkins.Google Scholar
White, E., Cheung, P., Silverstone, T. (1993) Depot antipsychotics in bipolar affective disorder. International Clinical Psychopharmacology, 8, 119–122.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.